Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.

NCI renews IU Simon Comprehensive Cancer Center’s designation

NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.

November 15, 2024

Vol.50 No.43

Clinical

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

In an industry that set its sights on reshaping cancer detection, GRAIL Inc. had the appearance of a pioneer.

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

Clinical Roundup

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.

October 25, 2024

Vol.50 No.40

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level.

October 18, 2024

Vol.50 No.39

By Claire Marie Porter

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

YOU MAY BE INTERESTED IN

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

NCI renews IU Simon Comprehensive Cancer Center’s designation

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Renew today!

Subscriber content

Never miss an issue!

Login

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

YOU MAY BE INTERESTED IN

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

NCI renews IU Simon Comprehensive Cancer Center’s designation

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Preclinical data suggest WRN inhibitor may be viable treatment for MSI-H tumors

Climate change exacerbates cancer disparitiesAmid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem

Never miss an issue!

Login

Climate change exacerbates cancer disparities
Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem